heat shock protein family A (Hsp70) member 12AGenealiases: []
Q-omics provides the consensus-scored HSPA12A profile across patient tissues and cancer cell-line models. HSPA12A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HSPA12A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, HSPA12A protein abundance shows 34,134 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where HSPA12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA12A survival associations across molecular data types. HSPA12A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA12A RNA expression–survival associations across cancer types. High HSPA12A expression shows unfavorable associations in KIRP, BLCA, LUAD, ACC and STAD, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HSPA12A RNA expression.
This table summarizes HSPA12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HSPA12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA12A shows lower tumor expression in KICH, THCA, BLCA, UCEC and KIRC and higher tumor expression in HNSC. The KICH box plot shows higher HSPA12A RNA expression in normal versus tumor tissue (log2 FC = −2.725, t-test p < 0.001).
This table shows molecular features associated with HSPA12A in patient tissues and cancer cell lines. In patient samples, HSPA12A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPA12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
